Recent Updates
Recently added Catalysts
ARWR Positive Sentiment Score: 85/100

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

Friday, April 24, 2026 1 min read
Key Takeaway: Arrowhead Pharmaceuticals has received a positive opinion from the EMA CHMP recommending the approval of REDEMPLO® (plozasiran) for reducing triglyceride levels in adults with familial chylomicronemia syndrome (FCS). This siRNA medicine is intended as an adjunct to diet. FCS is a condition that is often underdiagnosed, impacting a significant number of individuals.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive opinion from EMA CHMP for REDEMPLO® approval.
  • Potential to significantly reduce triglyceride levels in FCS patients.
  • Addresses an underdiagnosed condition affecting many adults.

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion, recommending the approval of REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS remains widely underdiagnosed and affects an estimated 1 to

Frequently Asked Questions

What is REDEMPLO® used for?

REDEMPLO® is used to reduce triglyceride levels in adults with familial chylomicronemia syndrome.

What did the EMA CHMP recommend?

The EMA CHMP recommended the approval of REDEMPLO® for treating FCS.

Why is FCS significant?

Familial chylomicronemia syndrome is often underdiagnosed and affects many adults.

What type of medicine is REDEMPLO®?

REDEMPLO® is a small interfering RNA (siRNA) medicine.

Tags: ARWR Viatris Investor Conferences Healthcare Arrowhead Pharmaceuticals REDEMPLO plozasiran FCS triglycerides
Last updated: Apr 24, 2026